Evoke Pharma, Inc. (EVOK): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVOK Stock Summary
- EVOK has a market capitalization of $8,792,274 -- more than approximately just 3.46% of US stocks.
- As for revenue growth, note that EVOK's revenue has grown 55.04% over the past 12 months; that beats the revenue growth of 86.18% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EVOK comes in at -84.67% -- higher than that of just 6.9% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to EVOKE PHARMA INC, a group of peers worth examining would be XOMA, ITP, SKIN, BYRN, and SGA.
- EVOK's SEC filings can be seen here. And to visit EVOKE PHARMA INC's official web site, go to www.evokepharma.com.
EVOK Valuation Summary
- In comparison to the median Healthcare stock, EVOK's price/sales ratio is 142.11% higher, now standing at 4.6.
- EVOK's price/sales ratio has moved NA NA over the prior 115 months.
Below are key valuation metrics over time for EVOK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EVOK | 2023-03-17 | 4.6 | 1.7 | -1.2 | -0.3 |
| EVOK | 2023-03-16 | 5.4 | 2.0 | -1.4 | -0.5 |
| EVOK | 2023-03-15 | 5.3 | 2.0 | -1.4 | -0.5 |
| EVOK | 2023-03-14 | 5.6 | 2.1 | -1.4 | -0.6 |
| EVOK | 2023-03-13 | 5.8 | 2.2 | -1.5 | -0.6 |
| EVOK | 2023-03-10 | 5.8 | 2.2 | -1.5 | -0.6 |
EVOK Growth Metrics
- The 4 year price growth rate now stands at -49.63%.
- Its 5 year cash and equivalents growth rate is now at -71.8%.
- Its 2 year net income to common stockholders growth rate is now at -16.62%.
The table below shows EVOK's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 2.072846 | -6.08686 | -8.093271 |
| 2022-06-30 | 2.171195 | -10.87807 | -8.048859 |
| 2022-03-31 | 1.946035 | -11.01486 | -8.106122 |
| 2021-12-31 | 1.618076 | -12.35294 | -8.537952 |
| 2021-09-30 | 1.280525 | -12.06725 | -9.133452 |
| 2021-06-30 | 0.350076 | -7.98564 | -9.293105 |
EVOK Price Target
For more insight on analysts targets of EVOK, see our EVOK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
EVOK Stock Price Chart Interactive Chart >
EVOK Price/Volume Stats
| Current price | $2.62 | 52-week high | $16.80 |
| Prev. close | $2.63 | 52-week low | $1.37 |
| Day low | $2.60 | Volume | 15,800 |
| Day high | $2.88 | Avg. volume | 36,616 |
| 50-day MA | $3.46 | Dividend yield | N/A |
| 200-day MA | $2.64 | Market Cap | 8.76M |
Evoke Pharma, Inc. (EVOK) Company Bio
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Latest EVOK News From Around the Web
Below are the latest news stories about EVOKE PHARMA INC that investors may wish to consider to help them evaluate EVOK as an investment opportunity.
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Image 1 All-Cause HCRU in the Pre-nasal MCP period vs. Post-nasal MCP period Image 2 Nausea, Vomiting, and DGP-associated HCRU in the Pre-nasal MCP period vs. Post-nasal MCP Period SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclo |
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial ResultsFiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, |
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. Management will host a conference call on Tuesday, March 21, 2023, at 4:30 p.m. ET |
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary SessionDistinguished event features the year’s best abstracts and invited speakers in their fieldsSOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that its abstract entitled “Reducing Real-World |
Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against GimotiStipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case FiledSOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI® patent infringement case (Civil Action No. 1:22-cv-02019) in the Uni |
EVOK Price Returns
| 1-mo | -20.36% |
| 3-mo | 0.00% |
| 6-mo | 34.39% |
| 1-year | -57.61% |
| 3-year | -76.27% |
| 5-year | -89.45% |
| YTD | -2.24% |
| 2022 | -59.39% |
| 2021 | -78.68% |
| 2020 | 59.26% |
| 2019 | -34.68% |
| 2018 | 9.73% |
Loading social stream, please wait...